[go: up one dir, main page]

PL3406633T3 - Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania - Google Patents

Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania

Info

Publication number
PL3406633T3
PL3406633T3 PL18163581T PL18163581T PL3406633T3 PL 3406633 T3 PL3406633 T3 PL 3406633T3 PL 18163581 T PL18163581 T PL 18163581T PL 18163581 T PL18163581 T PL 18163581T PL 3406633 T3 PL3406633 T3 PL 3406633T3
Authority
PL
Poland
Prior art keywords
multispecific
antibodies
methods
same
activatable
Prior art date
Application number
PL18163581T
Other languages
English (en)
Inventor
Bryan Allen Irving
Daniel Robert Hostetter
Chihunt WONG
Henry Bernard LOWMAN
James William WEST
Sherry Lynn LA PORTE
Original Assignee
Cytomx Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51299065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3406633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytomx Therapeutics Inc. filed Critical Cytomx Therapeutics Inc.
Publication of PL3406633T3 publication Critical patent/PL3406633T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
PL18163581T 2013-07-25 2014-07-25 Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania PL3406633T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361858402P 2013-07-25 2013-07-25
EP18163581.4A EP3406633B1 (en) 2013-07-25 2014-07-25 Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EP14748461.2A EP3024851B1 (en) 2013-07-25 2014-07-25 Multispecific antibodies, multispecific activatable antibodies and methods of using the same
PCT/US2014/048289 WO2015013671A1 (en) 2013-07-25 2014-07-25 Multispecific antibodies, multispecific activatable antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
PL3406633T3 true PL3406633T3 (pl) 2022-05-23

Family

ID=51299065

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18163581T PL3406633T3 (pl) 2013-07-25 2014-07-25 Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania

Country Status (17)

Country Link
US (2) US11161906B2 (pl)
EP (3) EP4067383A1 (pl)
JP (4) JP6693872B2 (pl)
KR (1) KR102216088B1 (pl)
CN (2) CN105722859B (pl)
AU (2) AU2014292924B2 (pl)
BR (1) BR112016001611B1 (pl)
CA (1) CA2918795A1 (pl)
DK (2) DK3024851T3 (pl)
ES (2) ES2912932T3 (pl)
HR (1) HRP20220553T1 (pl)
IL (1) IL243752B (pl)
PL (1) PL3406633T3 (pl)
PT (1) PT3406633T (pl)
RS (1) RS63152B1 (pl)
RU (1) RU2727836C2 (pl)
WO (1) WO2015013671A1 (pl)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
HRP20240722T1 (hr) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
JP6501521B2 (ja) 2012-08-24 2019-04-17 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
CA2913051C (en) 2013-05-28 2023-09-05 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
CA2918795A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
EP3083689B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN106662532B (zh) * 2014-03-26 2019-12-13 西门子医疗保健诊断公司 利用三种抗体的发光氧通道免疫测定及其生产和使用方法
DK3148581T3 (da) 2014-05-30 2020-01-13 Henlix Biotech Co Ltd Anti-epidermal vækstfaktorreceptor (egfr)-antistoffer
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CN107124884B (zh) * 2014-07-25 2022-11-01 纪念斯隆-凯特林癌症中心 双特异性her2和cd3结合分子
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AU2015348595B2 (en) 2014-11-20 2021-06-10 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against FOLR1 and CD3
EP3747905A1 (en) 2014-11-20 2020-12-09 F. Hoffmann-La Roche AG Common light chains and methods of use
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
CA2972800A1 (en) * 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
AU2016206707A1 (en) * 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
JP2018510842A (ja) 2015-02-05 2018-04-19 中外製薬株式会社 イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ−８に結合する抗体、およびその使用
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
LT3292149T (lt) * 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
JP6841754B2 (ja) 2015-05-13 2021-03-10 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
WO2016184426A1 (en) * 2015-05-20 2016-11-24 Tse-Wen Chang Molecular constructs with targeting and effector elements and their applications
JP6688551B2 (ja) 2015-05-21 2020-04-28 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
MX2018000714A (es) 2015-07-21 2019-11-18 Dyax Corp Un inhibidor de anticuerpo monoclonal de factor xiia.
EP3328427B1 (en) * 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
AU2016306320B2 (en) * 2015-08-11 2022-04-14 Osaka University Antibody
KR20180038560A (ko) 2015-08-28 2018-04-16 아뮤닉스 오퍼레이팅 인코포레이티드 키메라 폴리펩티드 조립체와 이의 제조 및 사용 방법
EA039736B1 (ru) * 2015-09-15 2022-03-04 Сайтомкс Терапьютикс, Инк. Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения
ES2769958T3 (es) 2015-09-18 2020-06-29 Prometheus Biosciences Inc Concentrados de sabor con una textura fluida con base en dos almidones
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
MX2018005785A (es) 2015-11-09 2019-04-04 Scherer Technologies Llc R P Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
WO2017120534A1 (en) * 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
UA127308C2 (uk) * 2016-03-22 2023-07-19 Ф. Хоффманн-Ля Рош Аг Активована протеазою біспецифічна молекула, яка зв'язує т-клітини
CN108884170A (zh) * 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性分子
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
MX2018014227A (es) 2016-05-20 2019-08-22 Harpoon Therapeutics Inc Proteinas de union de cadena unica de fragmento variable cd3.
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
AU2017345479B2 (en) * 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3538152A4 (en) * 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
MX2019005438A (es) 2016-11-15 2019-08-16 Genentech Inc Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
AU2017371225A1 (en) 2016-12-09 2019-05-16 Seagen Inc. Bivalent antibodies masked by coiled coils
EP3555620A1 (en) * 2016-12-13 2019-10-23 H. Hoffnabb-La Roche Ag Method to determine the presence of a target antigen in a tumor sample
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN112661853A (zh) * 2017-02-27 2021-04-16 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2或紧密连接蛋白18.2的多特异结合蛋白
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3607053A4 (en) * 2017-03-29 2021-04-07 Taipei Medical University ANTIGEN-SPECIFIC T-CELLS AND USES THEREOF
EP3601346A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN108690138A (zh) * 2017-04-12 2018-10-23 鸿运华宁（杭州）生物医药有限公司 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
BR112019024632A2 (pt) * 2017-05-23 2020-06-16 Dragonfly Therapeutics, Inc. A proteína de ligação nkg2d, cd16 e um tumor-antigénio associado
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP3645048A4 (en) * 2017-06-25 2021-06-16 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
WO2019005641A1 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. MULTI-SPECIFIC ANTIBODIES AND ASSOCIATED PRODUCTION AND USE PROCESSES
IL313468A (en) * 2017-06-25 2024-08-01 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
KR20200031113A (ko) * 2017-07-20 2020-03-23 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체의 특성을 정성적 및/또는 정량적으로 분석하는 방법 및 이의 용도
US11623965B2 (en) 2017-08-16 2023-04-11 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
IL273119B2 (en) 2017-09-08 2023-10-01 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
EP4435007A3 (en) 2017-10-13 2024-12-25 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
SG11202004579RA (en) * 2017-12-11 2020-07-29 Triphase Res And Development Iii Corp Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
KR20200132875A (ko) 2018-02-20 2020-11-25 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
AU2019262520A1 (en) 2018-05-04 2021-01-14 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
SG11202011309SA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B2 (en) 2018-05-14 2023-07-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
IL311536A (en) * 2018-06-04 2024-05-01 Tufts College Binder-drug conjugates activated in the microenvironment and their related uses
SG11202012405WA (en) * 2018-06-14 2021-01-28 Bioatla Inc Multi-specific antibody constructs
JP7651450B2 (ja) 2018-07-24 2025-03-26 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
US20210236636A1 (en) * 2018-07-31 2021-08-05 Amgen Inc. Pharmaceutical formulations of masked antibodies
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
EP3863721A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
JP2022532217A (ja) 2019-05-14 2022-07-13 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CN115135628A (zh) 2019-06-17 2022-09-30 泰克沃尔科斯制药有限公司 快速高效点击释放的化合物
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
KR20210043475A (ko) 2019-10-10 2021-04-21 주식회사 와이바이오로직스 다중 특이적 융합 단백질 및 이의 용도
US12240907B2 (en) 2019-11-05 2025-03-04 Regeneron Pharmaceuticals, Inc. N-terminal scFv multispecific binding molecules
CA3155981A1 (en) 2019-11-14 2021-05-20 William Winston Activatable cytokine polypeptides and methods of use thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
JP2023504620A (ja) * 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
CA3168832A1 (en) 2020-01-29 2021-08-05 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
TW202200619A (zh) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
US20210317188A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
WO2021226193A1 (en) 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
WO2022032037A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il23 receptor synthetic cytokines and methods of use
CA3190463A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il27r.alpha. binding molecules and methods of use
EP4192489A4 (en) 2020-08-05 2024-12-11 Synthekine, Inc. IL2RB-BINDING MOLECULES AND METHODS OF USE
KR20250028534A (ko) 2020-08-05 2025-02-28 신테카인, 인크. Il10 수용체 결합 분자 및 사용 방법
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
WO2022031929A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12rb1-binding molecules and methods of use
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
WO2022031871A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Compositions and methods related to il27 receptor binding
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
EP4192863A2 (en) 2020-08-05 2023-06-14 Synthekine, Inc. Il2rg binding molecules and methods of use
US20240034806A1 (en) * 2020-12-09 2024-02-01 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
JP2024514818A (ja) * 2021-04-08 2024-04-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および増殖のための方法ならびに二重特異性抗体との組合せ
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
CA3235018A1 (en) 2021-10-15 2023-04-20 Leila M. BOUSTANY Activatable polypeptide complex
JP2024539650A (ja) 2021-10-15 2024-10-29 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能なポリペプチド複合体
WO2023150672A1 (en) * 2022-02-04 2023-08-10 Duke University Compositions for and methods of treating hematological cancers
US20230293688A1 (en) * 2022-02-11 2023-09-21 Interius Biotherapeutics, Inc. Fusogenic rhabdovirus glycoproteins and uses thereof
CN114316062B (zh) * 2022-03-02 2022-06-07 珠海臻谱基因科技有限公司北京分公司 靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
CN119013299A (zh) 2022-04-13 2024-11-22 基因泰克公司 莫苏尼妥珠单抗的药物组合物及使用方法
WO2024104988A1 (en) * 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
WO1991001752A1 (en) 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1286700A2 (en) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
SI1517921T1 (sl) * 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
ATE455127T1 (de) 2003-05-31 2010-01-15 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
ATE447611T1 (de) 2003-08-18 2009-11-15 Univ California Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon
ES2358427T3 (es) 2003-10-16 2011-05-10 Micromet Ag Elementos de unión a cd-3 desinmunizados multiespecíficos.
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7666817B2 (en) 2005-08-31 2010-02-23 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
UA92505C2 (ru) 2005-09-12 2010-11-10 Новиммюн С.А. Композиции на основе антитела против cd3
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res (Munich) Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
EP1993608A1 (en) 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
WO2007147001A2 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
LT2520590T (lt) 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
JP6035009B2 (ja) * 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
PT2356153T (pt) 2008-10-01 2016-07-15 Amgen Res (Munich) Gmbh Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
CN102292352A (zh) 2008-10-10 2011-12-21 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
US8895702B2 (en) * 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
JP5851842B2 (ja) * 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
DK3903829T3 (da) 2009-02-13 2023-06-26 Immunomedics Inc Immunkonjugater med en intracellulær spaltelig binding
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
US20100241584A1 (en) * 2009-03-20 2010-09-23 Bank Of America Flexible design pension account
US9315584B2 (en) 2009-03-25 2016-04-19 Tohoku University LH-type bispecific antibody
NZ596711A (en) 2009-05-01 2013-11-29 Dual variable domain immunoglobulins and uses thereof
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
TWI452135B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
TW201311710A (zh) * 2011-06-28 2013-03-16 Daiichi Sankyo Co Ltd 磷酸酯衍生物
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR101886983B1 (ko) 2011-08-23 2018-08-08 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
JP6159724B2 (ja) 2011-08-23 2017-07-05 ロシュ グリクアート アーゲー Ｔ細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
IN2014MN02635A (pl) * 2012-06-22 2015-10-16 Cytomx Therapeutics Inc
EP2872170A4 (en) 2012-07-13 2016-06-22 Zymeworks Inc ASYMMETRIC BISPECIFIC HETERODIMERS WITH ANTI-CD3 CONSTRUCTS
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9487590B2 (en) * 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
US10261083B2 (en) * 2013-01-04 2019-04-16 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
EP3003387A1 (en) * 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
KR20230073341A (ko) 2013-07-05 2023-05-25 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CA2918795A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015013579A1 (en) * 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
IL270562B (en) * 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Matriptase and u-plasminogen activator polypeptide substrates and other cleanable moieties, compositions comprising same and uses thereof
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
LT3292149T (lt) * 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3406633A1 (en) 2018-11-28
CN105722859A (zh) 2016-06-29
EP3024851B1 (en) 2018-05-09
PT3406633T (pt) 2022-05-04
JP2024083331A (ja) 2024-06-20
RU2016106115A (ru) 2017-08-30
RU2020123264A (ru) 2020-10-14
EP3406633B1 (en) 2022-03-02
AU2020200981B2 (en) 2021-11-18
EP3024851A1 (en) 2016-06-01
US11161906B2 (en) 2021-11-02
KR20160035065A (ko) 2016-03-30
AU2020200981A1 (en) 2020-02-27
AU2014292924B2 (en) 2019-11-21
NZ716064A (en) 2022-03-25
US20210238291A1 (en) 2021-08-05
RU2727836C2 (ru) 2020-07-24
JP2016525551A (ja) 2016-08-25
RS63152B1 (sr) 2022-05-31
HRP20220553T1 (hr) 2022-06-10
DK3406633T3 (da) 2022-03-28
RU2016106115A3 (pl) 2018-07-24
AU2014292924A1 (en) 2016-02-11
ES2683268T3 (es) 2018-09-25
ES2912932T3 (es) 2022-05-30
KR102216088B1 (ko) 2021-02-15
IL243752A0 (en) 2016-04-21
WO2015013671A1 (en) 2015-01-29
NZ755670A (en) 2022-03-25
JP2022065174A (ja) 2022-04-26
DK3024851T3 (en) 2018-08-06
CN105722859B (zh) 2021-05-07
JP2020114872A (ja) 2020-07-30
EP4067383A1 (en) 2022-10-05
BR112016001611A2 (pt) 2017-08-29
JP6693872B2 (ja) 2020-05-13
JP7036860B2 (ja) 2022-03-15
CN113150164A (zh) 2021-07-23
US20150079088A1 (en) 2015-03-19
BR112016001611B1 (pt) 2024-01-09
IL243752B (en) 2021-10-31
CA2918795A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
PT3406633T (pt) Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
HK1250036A1 (zh) 抗cd 166抗體，可活化抗cd 166抗體及其使用方法
HK1250037A1 (zh) 抗-itga3抗體、可活化的抗-itga3抗體、及其使用方法
IL261743B (en) and their uses 33–il antibodies against
HK1250035A1 (zh) 抗cd 71抗體，可活化抗cd 71抗體及其使用方法
IL254458A0 (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies and methods of using them
IL261547B (en) Antibodies against pesidine and their uses
ZA201602792B (en) Microfluidic devices, and methods of making and using the same
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
EP3003390A4 (en) Anti-c10orf54 antibodies and uses thereof
EP3060580A4 (en) Anti-podocalyxin antibodies and methods of using the same
IL243790A0 (en) Devices, kits and methods of connection
AU2013901830A0 (en) Antibodies and uses thereof